Bruker announces majority investment in Mimetas, combining complementary offerings to advance drug discovery
10 August 2026
Bruker Corporation, a US-based company specialized in high-performance scientific instruments and high-value analytical solutions announced a major investment in Mimetas, a leading developer of organ-on-a-chip platforms and a CRO headquartered in the Netherlands.
Under the terms of the deal, Mimetas will continue operating under its own brand and management. Integration of services and product portfolios of the two companies will bring together Mimetas' OrganoReady®, OrganoTEER®, OrganoFlow®, OrganoAccess™ and OrganoPlate® devices for basic research, disease modeling, and drug testing with Bruker’s preclinical imaging, multiomics, spatial and single-cell biology.
The combined capabilities will support pharmaceutical and biotechnology researchers with complementary tools and expertise to advance biomedical research.
“Human physiology-relevant tissue and disease models are becoming increasingly important for understanding disease biology and evaluating therapeutic candidates,” said Frank H. Laukien, President and CEO of Bruker Corporation. “The unique MIMETAS organ-on-a-chip platforms complement Bruker’s capabilities in multiomics, spatial biology and preclinical imaging. We believe that humanized Microphysiological Systems, or NAMs, have a bright future, and will be increasingly adopted in drug discovery, development and preclinical testing.”
“Joining Bruker creates opportunities to scale our platforms and make advanced human tissue models available to more researchers worldwide,” said Paul Vulto and Jos Joore, co-founders and co-CEOs of MIMETAS. “By combining our OrganoPlate and OrganoReady solutions with Bruker’s molecular and cellular characterization technologies, we aim to offer more integrated workflows for disease research, compound evaluation and drug development.”
Financial details of the transaction were not disclosed.
For weekly news, trends and insights on human‑based in vitro approaches, explore your access options.
